[go: up one dir, main page]

ATE183087T1 - Verwendung von beta-hydroxy-beta- methylbutyratsäuere zur förderung der stickstoffzurückhaltung beim menschen - Google Patents

Verwendung von beta-hydroxy-beta- methylbutyratsäuere zur förderung der stickstoffzurückhaltung beim menschen

Info

Publication number
ATE183087T1
ATE183087T1 AT94903563T AT94903563T ATE183087T1 AT E183087 T1 ATE183087 T1 AT E183087T1 AT 94903563 T AT94903563 T AT 94903563T AT 94903563 T AT94903563 T AT 94903563T AT E183087 T1 ATE183087 T1 AT E183087T1
Authority
AT
Austria
Prior art keywords
beta
hydroxy
hmb
humans
nitrogen retention
Prior art date
Application number
AT94903563T
Other languages
English (en)
Inventor
Steven L Nissen
Paul J Flakkol
Naji N Abumrad
Original Assignee
Univ Iowa State Res Found Inc
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25542600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE183087(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Iowa State Res Found Inc, Univ Vanderbilt filed Critical Univ Iowa State Res Found Inc
Application granted granted Critical
Publication of ATE183087T1 publication Critical patent/ATE183087T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT94903563T 1992-12-23 1993-12-09 Verwendung von beta-hydroxy-beta- methylbutyratsäuere zur förderung der stickstoffzurückhaltung beim menschen ATE183087T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/996,187 US5348979A (en) 1992-12-23 1992-12-23 Method of promoting nitrogen retention in humans

Publications (1)

Publication Number Publication Date
ATE183087T1 true ATE183087T1 (de) 1999-08-15

Family

ID=25542600

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94903563T ATE183087T1 (de) 1992-12-23 1993-12-09 Verwendung von beta-hydroxy-beta- methylbutyratsäuere zur förderung der stickstoffzurückhaltung beim menschen

Country Status (9)

Country Link
US (1) US5348979A (de)
EP (1) EP0637239B1 (de)
JP (1) JP2925326B2 (de)
AT (1) ATE183087T1 (de)
AU (1) AU664511B2 (de)
CA (1) CA2129541C (de)
DE (1) DE69325998T2 (de)
ES (1) ES2134340T3 (de)
WO (1) WO1994014429A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597843A (en) * 1995-06-07 1997-01-28 Houghten Pharmaceuticals Use of a substituted 1,3-benzodioxole to reduce a wasting condition
US5716926A (en) * 1996-07-26 1998-02-10 Paxton K. Beale Composition of pyruvate and protein and method for increasing protein concentration in a mammal
US5756469A (en) * 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
US20090253781A1 (en) * 2002-05-24 2009-10-08 Btg International Limited Therapeutic compositions
US6316038B1 (en) 1997-03-17 2001-11-13 Btg International Limited Therapeutic compositions
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
US6103764A (en) * 1997-11-07 2000-08-15 Iowa State University Research Foundation, Inc. Method for increasing the aerobic capacity of muscle
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
AU2620600A (en) * 1999-01-21 2000-08-07 Steroidogenesis Inhibitors International Composition of anti-hiv drugs and anti-cortisol compounds and method for decreasing the side effects of anti-hiv drugs in a human
DE50205794D1 (de) * 2001-05-18 2006-04-20 Lonza Ag Verfahren zur herstellung fester formulierungen von natrium-3-hydroxy-3-methylbutyrat
US20040048925A1 (en) * 2002-09-09 2004-03-11 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040106678A1 (en) * 2002-09-17 2004-06-03 Dobbins Thomas A Compositions for the parenteral administration of calcium and magnesium
US6812249B2 (en) * 2003-03-04 2004-11-02 Sal Abraham Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
GB0420856D0 (en) * 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
EP1778213B1 (de) 2004-07-16 2017-04-05 BTG International Limited Verfahren zur herstellung oligomerer verbindungen
EP1778615A4 (de) * 2004-07-20 2010-01-06 Btg Int Ltd Oligomere ketonverbindungen
US20070225252A1 (en) * 2004-07-23 2007-09-27 Gross Richard A Ketogenic Saccharides
EP1796658B1 (de) * 2004-09-21 2016-03-30 BTG International Limited Dopaminerge mimetika
US20070197645A1 (en) * 2004-09-21 2007-08-23 Martin Keith F Treatment of adhd
US20080317886A1 (en) * 2005-11-03 2008-12-25 Sparkman Dennis R Compositions for Preventing and Reducing Delayed Onset Muscle Soreness
EP2082738B1 (de) 2005-12-19 2015-09-16 Abbott Laboratories Verwendung von Beta-Hydroxy-Beta-Methylbutyrat zur Asthmabehandlung
US11173167B2 (en) 2008-12-09 2021-11-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9539224B2 (en) 2008-12-09 2017-01-10 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9259430B2 (en) 2008-12-09 2016-02-16 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9707241B2 (en) 2008-12-09 2017-07-18 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
US9770424B2 (en) 2008-12-09 2017-09-26 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
PL2381784T3 (pl) 2008-12-09 2019-01-31 Metabolic Technologies, Inc. Interwencyjny produkt odżywczy w celu poprawy funkcji i siły mięśni
PL2512236T3 (pl) * 2009-12-18 2017-06-30 Metabolic Technologies, Inc. Ulepszony sposób podawania beta-hydroksy-beta-metylomaślanu (hmb)
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
WO2011094557A1 (en) 2010-01-29 2011-08-04 Abbott Laboratories Nutritional emulsions comprising calcium hmb
AU2011210682A1 (en) 2010-01-29 2012-07-05 Abbott Laboratories Aseptically packaged nutritional liquids comprising HMB
TWI526161B (zh) * 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
EP2892522A4 (de) 2012-09-10 2016-01-20 Metabolic Technologies Inc Zusammensetzung aus hmb und atp und verfahren zur verwendung
US20150057346A1 (en) * 2013-08-23 2015-02-26 Abbott Laboratories Methods of maintaining intramuscular myoglobin levels, maintaining maximal aerobic capacity, and enhancing the oxidative capacity of muscle in a subject
US12208073B2 (en) 2015-09-16 2025-01-28 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
US10758504B2 (en) 2015-09-16 2020-09-01 Metabolic Technologies, Inc. Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
EP4049723A1 (de) 2016-01-21 2022-08-31 Metabolic Technologies, Inc. Zusammensetzungen und verfahren zur verwendung von beta-hydroxy-beta-methylbutyrat (hmb) zur modulation von autophagie und lipophagie
CN110167544A (zh) 2016-10-21 2019-08-23 代谢科技有限公司 β-羟基-β-甲基丁酸(HMB)和益生菌的组合物及使用方法
JOP20190146A1 (ar) * 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CU20200012A7 (es) 2017-08-14 2021-02-04 Axcella Health Inc Composiciones de aminoácidos para el tratamiento de enfermedad hepática
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
JP7202800B2 (ja) * 2018-07-13 2023-01-12 ライオン株式会社 水分散性組成物、食品組成物、水分散液及び泡立ち抑制方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4100161A (en) * 1974-04-15 1978-07-11 The Johns Hopkins University Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids
JPS51104039A (de) * 1975-03-07 1976-09-14 Sankyo Kasei Kogyo Kk
US4677121A (en) * 1985-01-22 1987-06-30 The Johns Hopkins University Method of inhibiting muscle protein degradation
US4764531A (en) * 1986-03-11 1988-08-16 Iowa State University Research Foundation, Inc. Method of feeding ketoisocaproate to laying chickens
US4760090A (en) * 1986-03-11 1988-07-26 Iowa State University Research Foundation, Inc. Method of feeding ketoisocaproate to cattle and sheep
SE8803144L (sv) * 1988-09-07 1990-03-08 Kabivitrum Ab Energisubstrat
DE3943424A1 (de) * 1989-12-30 1991-07-04 Nephro Medica Pharma Infusions- und injektionsloesung zur intravenoesen verabreichung
US5087472A (en) * 1990-01-30 1992-02-11 Iowa State University Research Foundation, Inc. Feed compositions for domestics animals containing hydroxymethylbutyrate
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US4992470A (en) * 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
US5097472A (en) * 1990-02-22 1992-03-17 Chenausky Peter P Preionized transversely excited laser

Also Published As

Publication number Publication date
AU5746394A (en) 1994-07-19
ES2134340T3 (es) 1999-10-01
DE69325998D1 (de) 1999-09-16
WO1994014429A1 (en) 1994-07-07
CA2129541A1 (en) 1994-07-07
JPH07507569A (ja) 1995-08-24
EP0637239B1 (de) 1999-08-11
DE69325998T2 (de) 2000-01-05
US5348979A (en) 1994-09-20
CA2129541C (en) 1999-05-11
EP0637239A1 (de) 1995-02-08
EP0637239A4 (de) 1996-12-04
AU664511B2 (en) 1995-11-16
JP2925326B2 (ja) 1999-07-28

Similar Documents

Publication Publication Date Title
ATE183087T1 (de) Verwendung von beta-hydroxy-beta- methylbutyratsäuere zur förderung der stickstoffzurückhaltung beim menschen
CA2142314A1 (en) Method of Reducing Blood Levels of Total Cholesterol and Low-Density Lipoprotein Cholesterol
ATE158182T1 (de) Arzneimittel sowie deren herstellung und deren verwendung bei der bekämpfung von schmerzen und/oder entzündungen an tieren und menschen
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
DK0850068T3 (da) Lipidekstrakt med antiinflammatorisk aktivitet
KR950031063A (ko) 프라바스타틴을 이용하여 관상 동맥 아테롬성 동맥경화증의 진행 속도를 감소시키는 방법
DE60115432D1 (de) Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
ATE288772T1 (de) Sicherheitsmechanismus zum vorbeugen von unbeabsichtigter patienteninjektion sowie methode
DE68909267D1 (de) Medikament zur Behandlung von fibrotischer Störung und antifibrotische Verbindung.
Verbov Cutaneous polyarteritis nodosa in a young child.
DE3575671D1 (de) Verwendung von saccharomyces-hefen fuer die herstellung eines arzneimittels gegen amoebiasis.
TWI263502B (en) Pharmaceutical preparation for treating ischemic disease of heart or limbs
Noble Failure of cefotaxime in the treatment of Yersinia enterocolitica sepsis despite in vitro susceptibility.
EP0880967A3 (de) Nephroprotektive Arzneimittel
Zachariah Effective penetration of doxycycline into the serum and aqueous humor
RU95109228A (ru) Способ лечения трофических язв
Cherng et al. Acute aphesia following tourniquet release in intravenous regional anesthesia with 0.75% lidocaine
ATE83931T1 (de) Methode fuer die behandlung von viraler gehirnentzuendung.
ATE40795T1 (de) Verwendung eines zerebral und peripher wirkenden antihypoxidotikums.
Patterson et al. Psychosexual study of patients and non-patient homosexual groups.
Coma-Canella et al. Haemodynamic effects of nifedipine, nitroglycerine and prazosin in pulmonary hypertension following ingestion of toxic oil
ES8500055A1 (es) Procedimiento para la obtencion de un medicamento a base de un derivado de pirazolinona.
Greene et al. The effect of age on ranitidine pharmacokinetics.
UA11276C2 (uk) Спосіб реабілітації хворих, які переhесли вірусhий гепатит